The University of Chicago Header Logo

Connection

Cheng-Kai Kao to Aged, 80 and over

Back to Details
This is a "connection" page, showing publications Cheng-Kai Kao has written about Aged, 80 and over.
Cheng-Kai Kao
Connection Strength
0.015
Aged, 80 and over
  1. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. Am Heart J. 2017 Mar; 185:93-100.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.